Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, immunogenicity, and tolerability of a
monoclonal antibody administered subcutaneously in the treatment of advanced cancers of the
ovary, breast, lung, prostate, colon or rectum that are either refractory to standard
therapies or for which therapies that may potentially be of major benefit do not exist.